Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

A Mocroft; J Rockstroh; V Soriano; O Kirk; JP Viard; S Caplinskas; J Gasiorowski; A Chiesi; AN Phillips; Jens Dilling Lundgren

Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

A Mocroft, J Rockstroh, V Soriano, O Kirk, JP Viard, S Caplinskas, J Gasiorowski, A Chiesi, AN Phillips, Jens Dilling Lundgren

13 Citationer (Scopus)

Abstrakt

Uptake of hepatitis C (HCV) treatment in HIV-coinfected patients is not well described. Of 2356 HCV-seropositive patients, 180 (7.6%) started HCV treatment with interferon-based therapies. In multivariate Poisson-regression models, there was a 38% increase per year in the incidence of starting HCV treatment (95% CI 26 - 51%, p<0.0001); this increased from 3.9 per 1000 person-years follow-up (PYFU) before 1998 (95% CI 1.6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe.

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Infectious Diseases
Vol/bind	38
Udgave nummer	11
Sider (fra-til)	1092-1097
ISSN	0036-5548
Status	Udgivet - 2006

Adgang til dokumentet

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17148084&query_hl=11&itool=pubmed_docsum

Citationsformater

Mocroft, A., Rockstroh, J., Soriano, V., Kirk, O., Viard, JP., Caplinskas, S., Gasiorowski, J., Chiesi, A., Phillips, AN., & Lundgren, J. D. (2006). Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scandinavian Journal of Infectious Diseases, 38(11), 1092-1097. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17148084&query_hl=11&itool=pubmed_docsum

Mocroft, A, Rockstroh, J, Soriano, V, Kirk, O, Viard, JP, Caplinskas, S, Gasiorowski, J, Chiesi, A, Phillips, AN & Lundgren, JD 2006, 'Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C', Scandinavian Journal of Infectious Diseases, bind 38, nr. 11, s. 1092-1097. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17148084&query_hl=11&itool=pubmed_docsum>

@article{af5698944b4747528e05f9beddaea69c,

title = "Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C",

abstract = "Uptake of hepatitis C (HCV) treatment in HIV-coinfected patients is not well described. Of 2356 HCV-seropositive patients, 180 (7.6%) started HCV treatment with interferon-based therapies. In multivariate Poisson-regression models, there was a 38% increase per year in the incidence of starting HCV treatment (95% CI 26 - 51%, p<0.0001); this increased from 3.9 per 1000 person-years follow-up (PYFU) before 1998 (95% CI 1.6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe.",

author = "A Mocroft and J Rockstroh and V Soriano and O Kirk and JP Viard and S Caplinskas and J Gasiorowski and A Chiesi and AN Phillips and Lundgren, {Jens Dilling}",

year = "2006",

language = "English",

volume = "38",

pages = "1092--1097",

journal = "Scandinavian Journal of Infectious Diseases",

issn = "0036-5548",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

AU - Mocroft, A

AU - Rockstroh, J

AU - Soriano, V

AU - Kirk, O

AU - Viard, JP

AU - Caplinskas, S

AU - Gasiorowski, J

AU - Chiesi, A

AU - Phillips, AN

AU - Lundgren, Jens Dilling

PY - 2006

Y1 - 2006

N2 - Uptake of hepatitis C (HCV) treatment in HIV-coinfected patients is not well described. Of 2356 HCV-seropositive patients, 180 (7.6%) started HCV treatment with interferon-based therapies. In multivariate Poisson-regression models, there was a 38% increase per year in the incidence of starting HCV treatment (95% CI 26 - 51%, p<0.0001); this increased from 3.9 per 1000 person-years follow-up (PYFU) before 1998 (95% CI 1.6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe.

AB - Uptake of hepatitis C (HCV) treatment in HIV-coinfected patients is not well described. Of 2356 HCV-seropositive patients, 180 (7.6%) started HCV treatment with interferon-based therapies. In multivariate Poisson-regression models, there was a 38% increase per year in the incidence of starting HCV treatment (95% CI 26 - 51%, p<0.0001); this increased from 3.9 per 1000 person-years follow-up (PYFU) before 1998 (95% CI 1.6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe.

M3 - Journal article

VL - 38

SP - 1092

EP - 1097

JO - Scandinavian Journal of Infectious Diseases

JF - Scandinavian Journal of Infectious Diseases

SN - 0036-5548

IS - 11

ER -

Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater